食管癌淋巴结转移研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.12.014

摘要/Abstract

摘要： 淋巴结是食管癌转移的最主要部位，淋巴结的转移状况是判断食管癌患者预后的重要因素。食管癌早期即可出现淋巴结的转移，其转移具有就近转移和特定区域高发的较固定规律，也具有广泛转移和跳跃性转移的特点。因此研究食管癌淋巴结的转移规律能够帮助确定食管癌患者手术淋巴结清扫的范围和食管癌的放疗照射靶区。

关键词: 食管肿瘤, 淋巴转移, 淋巴结切除术, 淋巴照射

Abstract: Lymph nodes （LN）are the main parts of the esophageal cancer metastasis, and the current status of LN is the important indicator of prognosis. LN metastasis appears in early stage of esophageal cancer. One side, LN metastasis easily appears in the regions near the tumor and some special areas. On the other side, LN metastasis has the characteristics of wide metastasis and skip metastasis. Therefore, the researches of the pattern of esophageal cancer lymph node metastasis can help to comform the scope of the esophageal cancer lymph node dissection and the target regions of radiotherapy.

Key words: Esophageal neoplasms, Lymphatic metastasis, Lymph node excision, Lymphatic irradiation

应吟吟, 许亚萍, 毛伟敏. 食管癌淋巴结转移研究进展[J]. 国际肿瘤学杂志, 2014, 41(12): 921-925.

YING Yin-Yin, XU Ya-Ping, MAO Wei-Min. Research progress of lymph node metastasis in esophageal cancer[J]. Journal of International Oncology, 2014, 41(12): 921-925.

参考文献

［1］王永岗, 汪良骏, 张德超, 等. 胸段食管鳞癌淋巴结转移特点及临床意义［J］. 中华肿瘤杂志, 2000, 22(3): 241243. ［2］ Kim DU, Lee JH, Min BH, et al. Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma［J］. J Gastroenterol Hepatol, 2008, 23(4): 619625. ［3］陈跃军, 邹求益, 朱广, 等. 胸段食管癌淋巴结转移特点的临床研究［J］. 中华胃肠外科杂志, 2013, 16(9): 835837. ［4］ Gaur P, Sepesi B, Hofstetter WL, et al. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer［J］. Cancer, 2011, 117(1): 6369. ［5］ Wu N, Pang LW, Chen ZM, et al. Tumour length is an independent prognostic factor of esophageal squamous cell carcinomas［J］. Chin Med J (Engl), 2012, 125(24): 44454448. ［6］刘超,葛红,买玲, 等. 胸段食管鳞癌淋巴结转移规律及其影响因素分析［J］. 中华肿瘤防治杂志, 2013, 20(13):10251029. ［7］ Kaneshiro DK, Post JC, Rybicki L, et al. Clinical significance of the duplicated muscularis mucosae in Barrett esophagusrelated superficial adenocarcinoma［J］. Am J Surg Pathol, 2011, 35(5): 697700. ［8］ Raja S, Rice TW, Goldblum JR, et al. Esophageal submucosa: the watershed for esophageal cancer［J］. J Thorac Cardiovasc Surg, 2011, 142(6): 14031411. ［9］ Feng JF, Zhao Q, Chen QX. Prognostic value of subcarinal lymph node metastasis in patients with esophageal squamous cell carcinoma［J］. Asian Pac J Cancer Prev, 2013, 14(5): 31833186. ［10］ Kunisaki C, Makino H, Kimura J, et al. Impact of lymphnode metastasis site in patients with thoracic esophageal cancer［J］. J Surg Oncol, 2010, 101(1): 3642. ［11］ Akutsu Y, Shuto K, Kono T, et al. The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma［J］. J Surg Oncol, 2012, 105(8): 756760. ［12］ Kelty CJ, Kennedy CW, Falk GL. Ratio of metastatic lymph nodes to total number of nodes resected is prognostic for survival in esophageal carcinoma［J］. J Thorac Oncol, 2010, 5(9): 14671471. ［13］冯键, 茅腾, 陈文虎, 等. 转移淋巴结的数量和范围对食管癌预后的影响［J］. 中华胃肠外科杂志, 2011, 14(9):715718. ［14］祝淑钗, 宋长亮, 沈文斌. 食管癌根治性切除术后患者预后的影响因素分析［J］. 中华肿瘤杂志, 2012, 34(4): 281286. ［15］孙志钢, 王洲, 刘相燕，等. pN0食管癌IvorLewis手术后淋巴结转移性复发的危险因素［J］. 中华胸心血管外科杂志, 2011, 27(2): 108111. ［16］ Koenig AM, Prenzel KL, Bogoevski D, et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma［J］. Ann Surg Oncol, 2009, 16(2): 454462. ［17］ Sato F, Shimada Y, Li Z, et al. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma［J］. Br J Surg, 2001, 88(3): 426432. ［18］ Prenzel KL, Hlscher AH, Drebber U, et al. Prognostic impact of nodal micrometastasis in early esophageal cancer［J］. Eur J Surg Oncol, 2012, 38(4): 314318. ［19］ Uenosono Y, Arigami T, Yanagita S, et al. Sentinel node navigation surgery is acceptable for clinical T1 and N0 esophageal cancer［J］. Ann Surg Oncol, 2011, 18(7): 20032009. ［20］ Thompson SK, Bartholomeusz D, Jamieson GG. Sentinel lymph node biopsy in esophageal cancer: should it be standard of care? ［J］. J Gastrointest Surg, 2011, 15(10): 17621768. ［21］ Groth SS, Virnig BA, Whitson BA, et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database［J］. J Thorac Cardiovasc Surg, 2010, 139(3): 612620. ［22］ Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph nodenegativeesophageal cancer［J］. Cancer, 2008, 112(6): 12391246. ［23］ Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer［J］. Ann Surg, 2010, 251(1): 4650. ［24］ Shridhar R, Hoffe SE, Almhanna K, et al. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy［J］. Ann Surg Oncol, 2013, 20(9): 30383043. ［25］ Zhu Z, Yu W, Li H, et al. Nodal skip metastasis is not a predictor of survival in thoracic esophageal squamous cell carcinoma［J］. Ann Surg Oncol, 2013, 20(9): 30523058. ［26］ Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3field dissection［J］. Ann Surg, 2004, 239(4): 483490. ［27］ Fang WT, Chen WH, Chen Y, et al. Selective threefield lymphadenectomy for thoracic esophageal squamous carcinoma［J］. Dis Esophagus, 2007, 20(3): 206211. ［28］ Ma JB, Song YP, Yu JM, et al. Feasibility of involvedfield conformal radiotherapy for cervical and upperthoracic esophageal cancer［J］. Onkologie, 2011, 34(11): 599604.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[5]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[6]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[7]	曾利武, 杜雨强, 张鹏, 陶凯雄. 直肠癌侧方淋巴结转移的影像评估进展[J]. 国际肿瘤学杂志, 2023, 50(4): 248-251.
[8]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[9]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[10]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[11]	戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[12]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天. pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[13]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[14]	周剑烽, 王铁君. 食管癌的靶向治疗及免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 237-242.
[15]	刘佳, 葛小林, 狄晓珂, 史玉静, 曾玉婷. 喜炎平注射液预防放射性食管炎的疗效分析[J]. 国际肿瘤学杂志, 2022, 49(3): 146-150.